StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report issued on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance NASDAQ:AKTX opened at $3.69 on Tuesday. Akari Therapeutics has a 12-month low of $2.81 and a 12-month high of $12.55. The stock’s […]

Leave a Reply

Your email address will not be published.

Previous post Valero Energy (NYSE:VLO) Rating Lowered to Hold at Tudor, Pickering, Holt & Co.
Next post ACADIA Pharmaceuticals (NASDAQ:ACAD) Rating Increased to Buy at StockNews.com